Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126197 | 0.86 | SGPL1 (0.30) | SGPL1S1PR1 | |
| SCHEMBL20126198 | 0.82 | CHKA (0.33) | CYP3A4APPCYP2C9CYP2D6CYP2C19 | |
| SCHEMBL20126307 | 0.80 | SGPL1 (0.32) | SGPL1S1PR1 | |
| SCHEMBL20126115 | 0.79 | SGPL1 (0.30) | SGPL1S1PR1 | |
| SCHEMBL20126304 | 0.79 | CYP2C9 (0.32) | CYP2C9SGPL1S1PR1 | |
| SCHEMBL20126181 | 0.79 | CYP3A4 (0.35) | CYP3A4APPCYP2C9CYP2D6CYP2C19 | |
| SCHEMBL20126229 | 0.78 | SGPL1 (0.31) | SGPL1S1PR1 | |
| SCHEMBL20126178 | 0.77 | CYP3A4 (0.33) | CYP3A4APPCYP2C9CYP2D6CYP2C19 | |
| SCHEMBL20126226 | 0.77 | CYP2C9 (0.31) | CYP2C9SGPL1S1PR1 | |
| SCHEMBL20126128 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | CYP3A4 537/4885APP 658/4885CYP2C9 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.